We have located links that may give you full text access.
ENGLISH ABSTRACT
JOURNAL ARTICLE
[Changes of antimicrobial resistance among nonfermenting gram-negative bacilli isolated from intensive care units from 1994 to 2001 in China].
Zhonghua Yi Xue za Zhi [Chinese medical journal] 2003 March 11
OBJECTIVE: To investigate the antimicrobial resistance among nonfermenting gram-negative bacilli isolated from intensive care units (ICUs) during the past 7 years in China.
METHODS: From 1994 to 2001, the minimal inhibitory concentrations (MICs) of imipenem and other ten antibiotics for 4450 strains of nosocomial nonfermenting bacteria isolated from the ICUs of 32 hospitals in China were determined by E test. WHONET-5 software was used to analyze the data.
RESULTS: The most predominant pathogens were Pseudomonas aeruginosa (46.9%), Acinetobacter spp. (31.0%), and Stenotrophomonas maltophilia (9.2%). The susceptibility rates of these nonfermenting gram-negative bacilli to cefoperazone/sulbactam, imipenem, ceftazidime, piperacillin/tazobactam, amikacin, cefepime, and ciprofloxacin were 78.6%, 77.0%, 70.1%, 69.5%, 69.9%, 63.0%, and 59.1% respectively. Imipenem and cefoperazone/sulbactam were the most active agents against nonfermenting bacilli other than S.maltophilia and Burkholderia cepacia with susceptible rates 84.2% and 77.4% respectively. From 1994 to 2001, the activity of these 11 antibiotics against Pseudomonas aeruginosa decreased; the susceptibility rates of the nonfermenting gram-negative bacilli to imipenem, ceftazidime, amikacin, cefoperazone/sulbactam, cefepime, and piperacillin/tazobactam ranged from 70.0% to 83.0%. The susceptibility rate of Acinetobacter spp. to imipenem was 95.0% and remained unchanged for years. The susceptibility rate to cefoperazone/sulbactam came second, however, it was decreased from 88.0% in 1996 to 69.0% in 2001. The susceptibility rates to ceftazidime, cefepime, piperacillin/tazobactam, ticarcillin/clavulanic acid, gentamicin, and ciprofloxacin ranged from 45% to 58%. The susceptibility of Stenotrophomonas maltophilia was the highest to cefoperazone/sulbactam, ceftazidime, and ticarcillin/clavulanic acid (78% approximately 85%). Cefoperazone/sulbactam, piperacillin/tazobactam, and imipenem inhibited 80% of Alcaligenes spp. Only cefoperazone/sulbactam and piperacillin/tazobactam inhibited 70% of the strains of Flavobacterium spp; and 73% approximately 86% of Burkholderia cepacia were susceptible to cefoperazone/sulbactam, piperacillin/tazobactam, ceftazidime, and cefepime.
CONCLUSION: In recent 7 years, the antimicrobial resistance among nonfermenting gram-negative bacilli has increased in China. Antibiotics policy is urgently needed in order to delay the resistance development.
METHODS: From 1994 to 2001, the minimal inhibitory concentrations (MICs) of imipenem and other ten antibiotics for 4450 strains of nosocomial nonfermenting bacteria isolated from the ICUs of 32 hospitals in China were determined by E test. WHONET-5 software was used to analyze the data.
RESULTS: The most predominant pathogens were Pseudomonas aeruginosa (46.9%), Acinetobacter spp. (31.0%), and Stenotrophomonas maltophilia (9.2%). The susceptibility rates of these nonfermenting gram-negative bacilli to cefoperazone/sulbactam, imipenem, ceftazidime, piperacillin/tazobactam, amikacin, cefepime, and ciprofloxacin were 78.6%, 77.0%, 70.1%, 69.5%, 69.9%, 63.0%, and 59.1% respectively. Imipenem and cefoperazone/sulbactam were the most active agents against nonfermenting bacilli other than S.maltophilia and Burkholderia cepacia with susceptible rates 84.2% and 77.4% respectively. From 1994 to 2001, the activity of these 11 antibiotics against Pseudomonas aeruginosa decreased; the susceptibility rates of the nonfermenting gram-negative bacilli to imipenem, ceftazidime, amikacin, cefoperazone/sulbactam, cefepime, and piperacillin/tazobactam ranged from 70.0% to 83.0%. The susceptibility rate of Acinetobacter spp. to imipenem was 95.0% and remained unchanged for years. The susceptibility rate to cefoperazone/sulbactam came second, however, it was decreased from 88.0% in 1996 to 69.0% in 2001. The susceptibility rates to ceftazidime, cefepime, piperacillin/tazobactam, ticarcillin/clavulanic acid, gentamicin, and ciprofloxacin ranged from 45% to 58%. The susceptibility of Stenotrophomonas maltophilia was the highest to cefoperazone/sulbactam, ceftazidime, and ticarcillin/clavulanic acid (78% approximately 85%). Cefoperazone/sulbactam, piperacillin/tazobactam, and imipenem inhibited 80% of Alcaligenes spp. Only cefoperazone/sulbactam and piperacillin/tazobactam inhibited 70% of the strains of Flavobacterium spp; and 73% approximately 86% of Burkholderia cepacia were susceptible to cefoperazone/sulbactam, piperacillin/tazobactam, ceftazidime, and cefepime.
CONCLUSION: In recent 7 years, the antimicrobial resistance among nonfermenting gram-negative bacilli has increased in China. Antibiotics policy is urgently needed in order to delay the resistance development.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app